Incidence of cancer and statin usage - Record linkage study

International Journal of Cancer

Volumn 126, Issue 1, 2010, Pages 279-284

  Haukka, Jari ^a,b   Sankila, Risto ^c   Klaukka, Timo ^d   Lonnqvist, Jouko ^b   Niskanen, Leo ^e   Tanskanen, Antti ^b   Wahlbeck, Kristian ^b   Tiihonen, Jari ^e  

^a Data Analysis and Interpretation Group   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c FINNISH CANCER REGISTRY   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cancer; Exposure; HMG CoA reductase inhibitors; Pharmacoepidemiology; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; DRUG USE; FEMALE; FINLAND; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER;

FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NEOPLASMS;

EID: 73449089467     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24536     Document Type: Article

References (20)

1. http://www.nam.fi/medicines/drug-consumption. National Agency for Medicines-Drug consumption statistics [Internet] [Aug 22, 2008]. Available at: http://www.nam.fi/medicines/drug-consumption
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ,The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-8.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-2016.
5. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003; 24:225-48.
6. Demierre M, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
7. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295: 74-80.
8. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007;120:833-43.
9. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancer risk: a literaturebased meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006;24:4808-17.
10. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008;44: 2122-32.
11. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007;131: 1282-8.
12. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007;99:32-40.
13. Yu O, Boudreau D, Buist D, Miglioretti D. Statin use and female reproductive organ cancer risk in a large population-based setting [Internet]. Cancer Causes Control [Dec 23, 2008]. Available at: http://dx.doi.org/10. 1007/s10552-008-9271-1
14. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-19.
15. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36.
16. Anonym. World Health Organization guidelines for ATC classification for DDD assignment. Oslo, Norway: WHO Collaboration Centre for Drug Statistics Methodology. Nordic Council on Medicines, 1999.
17. Anonym. Available at: http://www.whocc.no/atcddd/indexdatabase/
18. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a populationbased cancer registry. Experience in Finland. Acta Oncol 1994;33:365-9.
19. McCullagh P, Nelder J. Generalized linear models, 2nd edn. London:Chapman and Hall, 1994.
20. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303.